Zyga Receives New Patent Allowances for SImmetry® Sacroiliac Joint Fusion System

Zyga Receives New Patent Allowances for SImmetry® Sacroiliac Joint Fusion System

Share this story with your network

MINNETONKA, Minn., June 21, 2017 /PRNewswire/ — Zyga Technology, Inc., a medical device company focused on the design, development and commercialization of minimally invasive devices to treat underserved conditions of the lumbar spine, today announced the issuance of a new US Patent representing continued advancement of the SImmetry Sacroiliac Joint Fusion System.

US patent number 9,662,124 relates to the design of the company’s proprietary SImmetry Decorticator®. This surgical instrument enables surgeons to prepare the sacroiliac (SI) joint for fusion by creating bleeding bone and space for autologous bone graft. This is accomplished through a minimally-invasive, lateral approach that avoids disruption of supporting ligaments around the SI joint.

Earlier this year the Company released results of a 19-patient, prospective, multi-center study of Minimally Invasive Sacroiliac Joint Fusion Surgery with Decortication. At 24 months post-op, 94 percent of patients had evidence of bridging bone across the SI joint, with 83 percent categorized as solid fusion. Of patients with solid fusion, 88 percent of the joints were fused within the area of decortication, demonstrating the importance of this step in achieving fusion. In addition to fusion, the study demonstrated a 73 percent reduction in average pain. Based on these data, the Company is currently sponsoring the EVoluSIon Study, a prospective, 40-site, 250-patient trial to evaluate long-term fusion and pain reduction in patients receiving SImmetry® Sacroiliac Joint Fusion.

“Zyga remains committed to advancing true fusion technology and the field of SI joint fusion,” said Jim Bullock, president and CEO of Zyga. “Zyga now has seven issued patents related to preparing the SI joint to establish a true biologic fusion.  The expansion of our intellectual property and ongoing support of clinical trials such as the EVoluSIon study further demonstrate Zyga’s leadership in innovation for minimally-invasive spine surgery.”

The Centers for Disease Control and Prevention lists back problems as the second most common cause of disability in U.S. adultsi. It has been reported that approximately 20 percent of all chronic LBP derives from the sacroiliac jointii.

About Zyga Technology, Inc.

Zyga Technology, Inc. is dedicated to the research, development and commercialization of solutions that provide empirical clinical and economic value in the treatment of underserved conditions of the spine. The company is marketing the SImmetry® Sacroiliac Joint Fusion System, a minimally invasive procedure intended for conditions including sacroiliac joint disruptions and degenerative sacroiliitis, and is conducting a U.S. multicenter clinical study of the Glyder Facet Restoration Device, a non-fusion, minimally invasive technology intended to provide relief from lumbar facet pain. For more information, visit zyga.com.

i Centers for Disease Control and Prevention. Prevalence of disabilities and associated health conditions among adults—United States, 1999. JAMA. 2001; 285(12):1571-1572.
ii Cohen SP et al. Sacroiliac Joint Pain: A Comprehensive Review of Epidemiology, Diagnosis and Treatment. Expert Rev Neurother. 2013; 13(1):99-116

CONTACT:
Erin Morrison
Tel 952 698 9956
emorrison@zyga.com

SOURCE Zyga Technology, Inc.

Related Links

http://www.zyga.com

Leave a Comment

Your email address will not be published. Required fields are marked *

*